Tanel Kiik
Tervise- ja tööminister 26.04.2021
nr 10.1-13/473-2
Sotsiaalministeerium
Austatud härra minister
Edastame Teile Euroopa Komisjoni voliniku Stella Kyriakidese 24.04.2021 kirja nr Ares(2021)
2744646 (AstraZenecaga vaktsineerimise jätkamine).
Lugupidamisega
Marten Kokk
Esinduse asejuht Coreper I küsimustes
Lisa: voliniku kiri 2 lk
Tiiu Noobel +32 2227 4337
[email protected]
Rue Guimard 11/13 1040 Brüssel Tel: +32 2 227 39 10
[email protected] https://eu.mfa.ee/et/
Ref. Ares(2021)2744646 - 24/04/2021
STELLA KYRIAKIDES Rue de la Loi, 200
MEMBER OF THE EUROPEAN COMMISSION B-1049 Brussels – Berl 10/380
HEALTH AND FOOD SAFETY
[email protected]
Brussels, 24 April 2021
Dear Minister,
I would like to start by thanking all of you who further to my letter of the 12 April supported
the European Medicines Agency by sharing the necessary data and evidence regarding the
AstraZeneca vaccine. Thanks to your contribution the Agency adopted yesterday the interim
opinion requested by the European Commission under Article 5(3) of Regulation
(EC) 726/2004 on the further assessment of the AstraZeneca’s COVID-19 vaccine.
In its opinion, the Agency gives a more precise scientific assessment on the safety profile of
the AstraZeneca vaccine in the context of the benefits for different age groups and different
rates of infection. The conclusion is clear that the overall benefits of the AstraZeneca vaccine
in the prevention of COVID-19 outweigh risks of very rare side effects, including thrombosis
in combination with thrombocytopenia (TTS).
In particular, the Agency has reviewed the available data and the risk of thrombosis in
combination with thrombocytopenia, a very rare side effect, in the context of the benefits of
vaccination stratified by age and considering the background infection rate. The analyses
conducted show that the benefits of vaccination increase with age and higher infections rates.
Details on different scenarios of age and infection rate for hospitalisation, intensive care unit
admission and death, together with TTS risk based on different assumptions of vaccine
effectiveness and risk are presented in the Agency’s interim opinion. Key aspects of this
analysis have been presented graphically to support the contextualisation of the analysis. You
will be able to take this analysis into account in your national vaccination campaigns.
With regard to the second dose, the Agency has considered the alternative scenarios of
administering the AstraZeneca vaccine but it concluded that two separate doses of the
AstraZeneca vaccine should continue to be administered 4 to 12 weeks apart, in line with the
current marketing authorisation. Therefore, the European Medicines Agency’s
recommendation to continue giving a second dose of the AstraZeneca vaccine remains valid.
EU Health Ministers
Let me stress that this is an interim opinion of the Agency based on currently available data.
I would therefore like to ask you to continue to regularly submit the vaccination and
epidemiological data relating to the AstraZeneca vaccine. This will allow the Agency to
continue its assessment as new information becomes available and ultimately to issue a final
conclusion in due course.
In the meantime, the interim opinion gives a solid scientific basis to support you in making
decisions on how to best use the AstraZeneca vaccine as part of your vaccines portfolio,
taking into account the different national situations. I also trust that this opinion will help to
ensure as much as possible a European approach based on science, clarity and coherence –
let’s ensure that we provide this to our citizens.
I would also like to acknowledge the effort and commitment of the staff of European
Medicines Agency and the national medicines regulatory authorities. I know that the
pandemic has increased demands on national agencies’ resources. Therefore, I take this
opportunity to call on you to support your medicines regulatory authorities so that together we
can continue to deliver high quality scientific assessment for COVID-19 vaccines and
therapeutics needed to protect and treat our citizens.
Thank you very much for your support and continued cooperation.
Yours sincerely,
Electronically signed on 24/04/2021 09:41 (UTC+02) in accordance with article 11 of Commission Decision C(2020) 4482
Tiiu Noobel
From: SOLOMONIDOU Christiana <
[email protected]>
Sent: Saturday, 24 April 2021 09:47
To: 'AT PERM REP';
[email protected]; Mission.BrusselsEU@bg-
permrep.eu;
[email protected];
[email protected]; info@bruessel-
eu.diplo.de;
[email protected]; Esindus EL juures üldaadress;
[email protected];
[email protected];
[email protected];
[email protected]; courrier.bruxelles-
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
'
[email protected]';
[email protected];
[email protected];
'
[email protected]';
[email protected];
[email protected]; '
[email protected]';
[email protected];
[email protected];
[email protected]
Subject: Letter from EU Commissioner Stella Kyriakides addressed to EU Health Ministers
Attachments: 2021 04 24 Cover letter to Ambassadors.pdf; 2021 04 24 Letter to Health Ministers
Art_5_3.pdf
Dear Sir/Madam,
Please find enclosed a letter from the European Commissioner for Health and Food Safety, Mrs Stella Kyriakides, for
the attention of the EU Health Ministers, and the transmission letter addressed to the Ambassadors.
We would be grateful if you could transmit this correspondence to the attention of your respective Minister at your
best convenience.
Sincerely,
CHRISTIANA SOLOMONIDOU
Assistant to Ms Τove Ernst & Ms Karolina Herbout-Borczak
European Commission
Cabinet of Commissioner Stella Kyriakides
Health and Food Safety
BERL 10/400
B-1049 Brussels/Belgium
+32 229-90271
[email protected]
1